PAK1 Therapy for Autism – All packed and ready to go!
Following up on recent posts about PAK1 , whose presence is required for 70% of cancers to grow and MIT have implicated in several types of autism, I have collected all the data I can find to make trials of PAK1 inhibition in autism. I contacted the leading Japanese researcher who has developed PAK1 therapies for various kinds of tumor, mainly found in neurofibromatosis, but also brain tumors and even epilepsy. He suggested the dosage of the CAPE -rich propolis from New Zealand and also suggested another drug called Fingolimod/Gilenya . This drug is an immunomodulating drug, approved for treating multiple sclerosis , but it is also a PAK1 inhibitor. It appears to cross the blood brain barrier. The downside it that Gilenya is hugely expensive, costing around $50,000 a year. While Tonegawa's group at MIT continue to develop their new PAK1 inhibitors, I am concerned that they will end up with a drug costing as much as Gilenya, whic...